Exelixis, Inc. Class Action Lawsuit - EXEL

The filed complaint alleges that Exelixis, Inc. made materially false and/or misleading statements and/or failed to disclose that: Exelixis shares dropped in after-hours trading after the Company reported Q2 revenue of approximately $628.7 million, missing consensus estimates, and lowered and narrowed its full-year 2026 revenue outlook. The revenue shortfall came alongside an adjusted EPS beat of $0.91 per share. Investors sold on the top-line number. The Company attributed the reduced full-year outlook to a slower-than-expected ramp in its neuroendocrine-tumor business -- a franchise Exelixis had described to investors as a market-leading position for CABOMETYX in the oral second-line plus segment. The May 5, 2026 first quarter earnings call, Chief Financial Officer Christopher Senner stated: "Finally, we are reiterating our full year 2026 financial guidance." That guidance was subsequently lowered.

In order to be eligible to join the EXEL class action lawsuit, you must have incurred a loss on shares of Exelixis, Inc. purchased during the class period listed above.